Learning Objectives:
After completing this activity, the learner will be able to:
1. Identify and diagnose catatonia using validated assessment tools and distinguish it from severe psychosis, negative symptoms of schizophrenia, and deception syndromes
2. Implement evidence-based treatment protocols for catatonia, including lorazepam challenge dosing, titration strategies up to 16mg daily, and appropriate use of alternative benzodiazepines during medication shortages
3. Develop individualized treatment plans incorporating NMDA antagonists, ECT referral criteria, and relapse prevention strategies for patients with refractory or recurrent catatonia
Original Release Date: February 01, 2026
Expiration Date: February 01, 2029
Expert: Scott Beach, M.D.
Medical Editors: Lizzie Samuels, P.M.H.N.P., Flavio Guzmán, M.D.
Relevant Financial Disclosures:
None of the faculty, planners, and reviewers for this educational activity has relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com
Instructions for Participation and Credit:
Participants must complete the activity online within the valid credit period noted above.
Follow these steps to earn CME credit:
- View the required educational content provided on this course page.
- Complete the Post-Activity Evaluation to provide the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
- Download your certificate.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
